Abstract:
The present invention relates to methods and kits for classifying an individual as being at risk of developing Alzheimer's disease, in particular Alzheimer's disease type-dementia.
Abstract:
A method for managing communication in a wireless mesh network comprising a plurality of wireless nodes and a wireless node for use in such network are described, wherein said method may comprise: providing a time slot schedule (frame), preferably a TDMA time slot schedule (frame), comprising one or more time slots, including a transmission time slot enabling a node to transmit a broadcast message, a reception time slot enabling a node to receive a broadcast message from one or more other nodes; and/or a sleep time slot for configuring said node in an idle state; and, assigning said time slots to nodes in said network on the basis of the position of said nodes in said network.
Abstract:
Novel radiotracer for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging are described. Specifically, the invention relates to 18 F-labeled afatinib suitable as a PET or SPECT tracer for imaging epidermal growth factor receptor (EGFR, erbB1) and human epidermal growth factor receptor 2 (Her2, erbB2), to a precursor compound for use in its synthesis, to methods for the preparation 18 F-iabeled afatinib, as well as to the use thereof in in vivo diagnosis, tumor imaging or patient stratification on the basis of mutational status of EGFR (erbB1) and Her2 (erbB2).
Abstract:
BRCA-deficiency signatures comprising differentially regulated proteins present in BRCA1-deficient tumors, and BRCA-deficiency signatures comprising nucleic acids isolated from BRCA1-deficient tumors, as well as methods of using the same, are disclosed.
Abstract:
The invention is directed to a process to separate compounds starting from a mixture of two or more compounds by performing the following steps:(a) passing a portion of a gaseous mixture of a carrier gas and the mixture of compounds through a GC column wherein two or more compounds of the mixture are discharged at a different time from the column. In a step (b) a fluid is added to the gaseous flow to obtain a flow comprising of the fluid as a gas, the carrier gas and the compounds. In a step (c) the flow of step (b) is cooled to obtain a flow comprising a gaseous phase comprising the carrier gas and a liquid phase comprising the condensed fluid and the compounds. In a step(d) the one or more liquid fractions from the flow of step (c)are isolated.
Abstract:
The present invention relates to an optical apparatus (202) comprising a sample support (219) and imaging means (2119) arranged, when said optical apparatus (202) is in use, to receive a first beam (2115) emanating from the sample support (219) under a first angle (2127) with respect to a reference axis (2131)wherein the optical apparatus (202) further comprises a reflector (217) and in that the imaging means (2119) are arranged to receive at least a second beam (2113, 211) emanating from the sample support (219) under a second angle (2129) with respect to the reference axis (2131),the second angle (2129) being different from the first angle (2127), the second beam (2113, 211) when passing from the sample support (219) to the imaging means (2119) being reflected by the reflector (217).
Abstract:
The blood-brain barrier (BBB) separates the blood and the central nervous system (CNS). Here it is disclosed that blood-brain barrier function can be increased with particular nucleic acid sequences, in particular in patients suffering from or diagnosed with Multiple Sclerosis. The use of compounds comprising such nucleic acid sequences for increasing blood-brain barrier function is described.
Abstract:
The present invention relates to a method of analysing a blood sample of a subject for the presence of a disease marker, said method comprising the steps of a) extracting nucleic acid from anucleated blood cells in said blood sample to provide an anucleated blood cells-extracted nucleic acid fraction, and b) analysing said anucleated blood cells-extracted nucleic acid fraction for the presence of a disease marker, wherein said disease marker is a disease-specific mutation in a gene of a cell of said subject, or wherein said disease marker is a disease-specific expression profile of genes of a cell of said subject.
Abstract:
A method for managing communication in a wireless mesh network comprising a plurality of wireless nodes and a wireless node for use in such network are described, wherein said method may comprise: providing a time slot schedule (frame), preferably a TDMA time slot schedule (frame), comprising one or more time slots, including a transmission time slot enabling a node to transmit a broadcast message, a reception time slot enabling a node to receive a broadcast message from one or more other nodes; and/or a sleep time slot for configuring said node in an idle state; and, assigning said time slots to nodes in said network on the basis of the position of said nodes in said network.
Abstract:
A suture device includes a needle operating device movable longitudinally with respect to a housing between at least an insertion position and a needle transfer position. The needle operating device includes an elongate operating element arranged extending from a distal end of the housing to or near a housing proximal end. A needle holder connected at a distal end of the operating element holds two or more needles, with free ends directed in proximal direction. The holder is movable with respect to a protection device between at least a protecting position shielding the free ends, and a non-protecting position for the same. A needle receive device at a distal end of the housing receives the free ends when the operating device is moved to the transfer position. In at least the insertion position the holder and the protection device are spaced longitudinally from the housing to receive a tissue therebetween.